SCHEMBL3207971

SCHEMBL3207971

CCCCCCCCCCCCCCCCCC(=O)Oc1coc(CO)cc1=O

nearest known ligand 0.68

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ELANE P08246 13/20 0.68
NPC1 O15118 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
RECQL P46063 1/20 0.45
RAB9A P51151 1/20 0.45
DAO P14920 1/20 0.45
POLM Q9NP87 1/20 0.43
POLK Q9UBT6 1/20 0.43
POLL Q9UGP5 1/20 0.43
POLH Q9Y253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL941862 1.00 ELANE (0.68) ELANENPC1CYP1A2CYP2C19RECQL
SCHEMBL126653 1.00 ELANE (0.68) ELANENPC1CYP1A2CYP2C19RECQL
SCHEMBL942542 0.89 ELANE (0.54) ELANENPC1CYP1A2CYP2C19RECQL
SCHEMBL13671134 0.87 ELANE (0.87) ELANE
SCHEMBL125979 0.87 ELANE (0.87) ELANE
SCHEMBL3022639 0.84 ELANE (0.61) ELANENPC1RAB9APOLMPOLK
SCHEMBL129441 0.83 RAB9A (0.51) ELANENPC1CYP1A2CYP2C19RECQL
SCHEMBL3395761 0.82 ELANE (0.59) ELANENPC1RECQLRAB9APOLM
SCHEMBL8129293 0.81 RAB9A (0.56) ELANENPC1CYP1A2CYP2C19RECQL
SCHEMBL8130917 0.81 RAB9A (0.56) ELANENPC1CYP1A2CYP2C19RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200289392-A1 A MELANOGENESIS INHIBITOR COMPOSITION DOW GLOBAL TECHNOLOGIES LLC (US) 2020-09-17 US claimed
CN-106943338-B Personalized beauty skin care product and preparation method thereof 南京支云松生物科技有限公司 2020-07-21 CN claimed
EP-3644947-A1 A MELANOGENESIS INHIBITOR COMPOSITION Dow Global Technologies LLC (US) 2020-05-06 EP claimed
CN-110769808-A Melanin production inhibitor composition 陶氏环球技术有限责任公司 2020-02-07 CN claimed
WO-2019005437-A1 A MELANOGENESIS INHIBITOR COMPOSITION DOW GLOBAL TECHNOLOGIES LLC (US) 2019-01-03 WO claimed
CN-106943338-A Personalized beauty care skin care item and preparation method thereof 何向锋 2017-07-14 CN claimed
CN-1259034-C Leech extract cosmetics and method for making same ZHOU WEIHAI (CN) 2006-06-14 CN claimed
CN-1522689-A Leech extract cosmetics and method for making same 周维海 2004-08-25 CN claimed
EP-0308543-B1 COMPOSITIONS FOR EXTERNAL APPLICATION Sansho Seiyaku Co., Ltd. (JP) 1993-09-22 EP claimed
US-4990330-A Skin whitening and sunscreen; Kojic acid of esters, glucosamine and derivatives, cystein SANSHO SEIYAKU CO., LTD. (JP) 1991-02-05 US claimed
US-4948577-A KOJIC ACID AND 4-/1,1-DIMETHYLETHYL/-4'-METHOXY DIBENZOYLMETHANE; PREVENT COLORING OF SKIN WHEN EXPOSED TO ULTRAVIOLET LIGHT SANSHO SEIYAKU CO., LTD. (JP) 1990-08-14 US claimed
US-4919921-A KOJIC ACID OR AN ESTER OF KOJIC ACID AND VITAMIN C OR A DERIVATIVE OF VITAMIN C SANSHO SEIYAKU CO., LTD. (JP) 1990-04-24 US claimed
EP-0308543-A1 Compositions for external application Sansho Seiyaku Co., Ltd. (JP) 1989-03-29 EP claimed
EP-0308919-A1 Compositions for topical use having melanin synthesis-inhibiting activity Sansho Seiyaku Co., Ltd. (JP) 1989-03-29 EP claimed
EP-0308918-A1 Compositions for topical use having melanin synthesis-inhibiting activity Sansho Seiyaku Co., Ltd. (JP) 1989-03-29 EP claimed
WO-2024132395-A1 COLOR STABILIZATION OF FORMULAE WITH AN INDOLE UNILEVER IP HOLDINGS B.V. (NL) 2024-06-27 WO disclosed
EP-4308071-A1 USE OF HORDENINE FOR TREATING CELLULAR SENESCENCE Unilever IP Holdings B.V. (NL) 2024-01-24 EP disclosed
EP-0308543-A1 Compositions for external application Sansho Seiyaku Co., Ltd. (JP) 1989-03-29 EP disclosed
US-4696813-A PLACENTA EXTRACT AND KOJIC ACID SANSHO SEIYAKU CO., LTD. (JP) 1987-09-29 US disclosed
EP-0208799-A1 Whitening cosmetic composition Sansho Seiyaku Co., Ltd. (JP) 1987-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289392-A1 A MELANOGENESIS INHIBITOR COMPOSITION TYR, MC1R, MITF ELANE 3929/4885NPC1 1539/4885CYP1A2 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.